AI

AI Therapeutics is a clinical-stage biopharmaceutical company that leverages artificial intelligence to accelerate the development of therapies for rare diseases and oncology. The company utilizes its proprietary Guardian Angel platform, which combines deep learning algorithms with high-throughput screening to match existing and novel drugs with specific patient populations. Their lead candidate, apilimod (LAM-002), is a first-in-class PIKfyve kinase inhibitor being evaluated for the treatment of B-cell malignancies and neurological disorders like ALS. By repurposing and optimizing small molecules through AI-driven insights, the company aims to significantly reduce the time and cost associated with traditional drug discovery. AI Therapeutics is part of the 4Catalyzer incubator, founded by entrepreneur Jonathan Rothberg.